Pent-Up Demand As GW Pharma’s Epidyolex Approved In Europe
Executive Summary
Drug will meet pent-up demand in Europe for clinically proven cannabis-based medicine for hard-to-treat epilepsy.
You may also be interested in...
NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat
Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.
US FDA Filing Mistake For Fintepla Dents Zogenix
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.